Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies

Current Heart Failure Reports

Volumn 10, Issue 4, 2013, Pages 321-330

  Givertz, Michael M ^a   Mann, Douglas L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Left ventricular recovery; Reverse remodeling

Indexed keywords

ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTITHYROID AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN G; ISOSORBIDE; PREDNISONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; TOXIN; TRASTUZUMAB;

ADJUVANT THERAPY; ALCOHOLIC CARDIOMYOPATHY; ARTICLE; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDITIS; CONGESTIVE CARDIOMYOPATHY; CONVALESCENCE; DRUG WITHDRAWAL; ENERGY TRANSFER; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTHYROIDISM; MYOCARDITIS; NONHUMAN; PERIPARTUM CARDIOMYOPATHY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TACHYCARDIA INDUCED CARDIOMYOPATHY; TAKOTSUBO CARDIOMYOPATHY;

CARDIOMYOPATHY, DILATED; CARDIOTOXINS; HUMANS; MYOCARDITIS; PROGNOSIS; RECOVERY OF FUNCTION; REMISSION, SPONTANEOUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENTRICULAR FUNCTION, LEFT;

EID: 84888074090     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0157-5     Document Type: Article

References (69)

1. Dec GW, Fuster V. Medical Progress: Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564.
2. Hellawell JL, Margulies KB. Myocardial Reverse Remodeling. Cardiovasc Ther. 2012;20:172-81.
3. • Mann DL, Barger PM, Burkhoff D. Myocardial recovery: myth, magic or molecular target. J Am Coll Cardiol. 2012;60:2465-72. Recent article that addresses the biology of LV recovery and reverse remodeling and that introduces the concept that end organ damage prevents restoration of LV function.
4. Dec Jr GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. N Engl J Med. 1985;312:885-90.
5. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509-13.
6. Duran N, Gunes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101:137-40.
7. Okada M, Tanaka H, Matsumoto K, Ryo K, Kawai H, Hirata K. Subclinical myocardial dysfunction in patients with reverse-remodeled dilated cardiomyopathy. J Am Soc Echocardiogr. 2012;25:726-32.
8. Gopinathannair R, Sullivan R, Olshansky B. Tachycardia-mediated cardiomyopathy: recognition and management. Curr Heart Fail Rep. 2009;6:257-64.
9. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-15.
10. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247-52.
11. Khasnis A, Jongnarangsin K, Abela G, Veerareddy S, Reddy V, Thakur R. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol. 2005;28:710-21.
12. Dandamudi G, Rampurwala AY, Mahenthiran J, Miller JM, Das MK. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Hear Rhythm. 2008;5:1111-4.
13. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006;27:1523-9.
14. Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118:397-409.
15. Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55:333-41.
16. Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007;50:448-52.
17. Booysen HL, Norton GR, Opie LH, Woodiwiss AJ. Reverse chamber remodelling following adrenergic-induced advanced cardiac dilatation and pump dysfunction. Basic Res Cardiol. 2012;107:238.
18. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 2011;306:277-86.
19. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93:483-7.
20. Poletto R, Janczak AM, Marchant-Forde RM, Marchant-Forde JN, Matthews DL, Dowell CA, et al. Identification of low and high frequency ranges for heart rate variability and blood pressure variability analyses using pharmacological autonomic blockade with atropine and propranolol in swine. Physiol Behav. 2011;103:188-96.
21. Laonigro I, Correale M, Di BM, Altomare E. Alcohol abuse and heart failure. Eur J Heart Fail. 2009;11:453-62.
22. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989;320:409-15.
23. Urbano-Marquez A, Estruch R, Fernandez-Sola J, Nicolas JM, Pare JC, Rubin E. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA. 1995;274:149-54.
24. Lazarevic AM, Nakatani S, Neskovic AN, Marinkovic J, Yasumura Y, Stojicic D, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol. 2000;35:1599-606.
25. • Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910-6. A recent article that addresses LV recovery in patients who are receiving chemotherapy. This study shows that that patients who have elevated levels of troponin after trastuzumab are less likely to recover LV function than patients who do not have elevated troponin levels.
26. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-33.
27. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-6.
28. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 world health organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-2.
29. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779-92.
30. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-9.
31. •• Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol. 2013;61:54-63. Carefully done study that examines longitudinal assessment of LV function in patients with recent onset dilated cardiomyopathy. This study also examined the utility of cardiac MRI and biomarkers for predicting LV recovery in a subset of patients.
32. Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol. 1994;23:553-9.
33. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269-75.
34. McCarthy III RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690-5.
35. Abboud J, Murad Y, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118:295-303.
36. Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, et al. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol. 2011;147:202-8.
37. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS, et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail. 2012;18:28-33.
38. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105:1303-8.
39. O'Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986;8:52-6.
40. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567-71.
41. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol. 1997;176:189-95.
42. Jardin F, Brun-Ney D, Auvert B, Beauchet A, Bourdarias JP. Sepsis-related cardiogenic shock. Crit Care Med. 1990;18:1055-60.
43. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-90.
44. McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, et al. Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy Results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 Study. J Am Coll Cardiol. 2011;58:1112-8.
45. Donghua Z, Jian P, Zhongbo X, Feifei Z, Xinhui P, Hao Y, et al. Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol. 2013;36:27-32.
46. Medi C, Kalman JM, Haqqani H, Vohra JK, Morton JB, Sparks PB, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791-7.
47. Parodi G, Bellandi B, Del PS, Barchielli A, Zampini L, Velluzzi S, et al. Natural history of tako-tsubo cardiomyopathy. Chest. 2011;139:887-92.
48. Looi JL, Wong CW, Khan A, Webster M, Kerr AJ. Clinical characteristics and outcome of apical ballooning syndrome in Auckland, New Zealand. Heart Lung Circ. 2012;21:143-9.
49. Samardhi H, Raffel OC, Savage M, Sirisena T, Bett N, Pincus M, et al. Takotsubo cardiomyopathy: an Australian single centre experience with medium term follow up. Intern Med J. 2012;42:35-42.
50. Umpierrez GE, Challapalli S, Patterson C. Congestive heart failure due to reversible cardiomyopathy in patients with hyperthyroidism. Am J Med Sci. 1995;310:99-102.
51. Riaz K, Forker AD, Isley WL, Hamburg MS, McCullough PA. Hyperthyroidism: a curable cause of congestive heart failure-three case reports and a review of the literature. Congest Heart Fail. 2003;9:40-6.
52. Nicolas JM, Fernandez-Sola J, Estruch R, Pare JC, Sacanella E, Urbano-Marquez A, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med. 2002;136:192-200.
53. Gavazzi A, De MR, Parolini M, Porcu M. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol. 2000;85:1114-8.
54. La Vecchia LL, Bedogni F, Bozzola L, Bevilacqua P, Ometto R, Vincenzi M. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol. 1996;19:45-50.
55. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859-65.
56. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer Jr CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-9.
57. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99:634-9.
58. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053-61.
59. Horgan SJ, Margey R, Brennan DJ, O'Herlihy C, Mahon NG. Natural history, management, and outcomes of peripartum cardiomyopathy: an Irish single-center cohort study. J Matern Fetal Neonatal Med. 2013;26:161-5.
60. Hu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93:488-90.
61. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet. 2009;104:125-7.
62. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35:701-5.
63. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441-6.
64. Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart. 2013;99:308-13.
65. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201:171-5.
66. Chau EM, Chow WH, Chiu CS, Wang E. Treatment and outcome of biopsy-proven fulminant myocarditis in adults. Int J Cardiol. 2006;110:405-6.
67. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8.
68. Goland S, Czer LS, Siegel RJ, Tabak S, Jordan S, Luthringer D, et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol. 2008;24:571-4.
69. Preeta R, Nair RR. Stimulation of cardiac fibroblast proliferation by cerium: a superoxide anion-mediated response. J Mol Cell Cardiol. 1999;31:1573-80.